☆ 4.6 Article

Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis

PHARMACEUTICALS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

Disease-specific interactome alterations via epichaperomics: the case for Alzheimer's disease

Stephen D. Ginsberg et al.

Summary: The article discusses the relationship between stressor-induced protein interactome network perturbations and the formation of pathologic scaffolds, proposing how epichaperomics can reliably obtain context-dependent interactomes to advance the definition, understanding, and control of complex disease interactome networks.

FEBS JOURNAL (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and In Vivo Proof of Concept of a Highly Potent DualInhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase forthe Treatment of Alzheimer's Disease

Sandra Codony et al.

Summary: The advent of multitarget drug discovery has brought hope for the treatment of multifactorial diseases. A new dual inhibitor has shown positive effects on neuroinflammation and memory impairment and exhibits favorable drug properties.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Review Chemistry, Medicinal

Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease

Elena F. Shevtsova et al.

Summary: Mitochondria-targeting drugs can be categorized into those compensating for energy deficit and inhibiting MPT, and neuroprotectors increasing mitochondrial resistance. However, monotherapy for patients with severe symptoms may not be effective, it is optimal to combine multiple targets for better outcomes.

MEDICINAL RESEARCH REVIEWS (2021)

添加到收藏夹

Review Chemistry, Medicinal

From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology

Claudia Albertini et al.

Summary: Despite the failures in drug discovery for complex neurodegenerative diseases like AD, the rise of awareness regarding polypharmacological approaches, using pharmaceutical agents acting on multiple targets, presents a promising avenue for restoring the diseased network and providing disease-modifying effects. Understanding the advantages and drawbacks of different modalities in drug discovery is crucial for developing successful AD multitarget drug-discovery endeavors. Researchers aiming to enter and progress in this field are encouraged to explore the full potential of AD polypharmacology.

MEDICINAL RESEARCH REVIEWS (2021)

添加到收藏夹

Review Chemistry, Medicinal

A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

Kundlik Gadhave et al.

Summary: The exact molecular mechanisms associated with Alzheimer's disease remain a mystery, making the utilization of signaling pathways as potential drug targets limited. It is necessary to find correlations and cross-talk between these pathways and establish different therapeutic targets for a better understanding of the biological events responsible for AD-related neurodegeneration. Consideration should be given to the central role of autophagy in AD and its interplay with other pathways as the finest therapeutic strategy.

MEDICINAL RESEARCH REVIEWS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches

Natalia F. F. Pirolla et al.

Summary: This article summarizes the therapeutic targets, drugs, and synthetic routes involved in Alzheimer's disease, as well as some bioactive compounds under development to illustrate recent research advances in medicinal chemistry. The importance of multi-target approaches, including examples from research projects, is emphasized to guide the search for more effective drug candidates. This review covers the period between 2001 and early 2020.

CURRENT DRUG TARGETS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Chalcones Acting as Inhibitors of Cholinesterases, β-Secretase and β-Amyloid Aggregation and other Targets for Alzheimer's Disease: A Critical Review

Giorgio Antoniolli et al.

Summary: This review highlights the potential of chalcones to act on multiple targets related to the pathophysiology of Alzheimer's disease. While chalcones have shown moderate to good potency against cholinesterases, research on their effects on other targets of the disease, such as amyloid peptide, has been increasing in recent years. One major challenge is the poor water solubility of chalcones, but strategies can be developed to overcome this limitation without compromising their biological activity.

CURRENT MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Review Neurosciences

From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease

Jazmin Alarcon-Esposito et al.

Summary: Alzheimer's disease is a common cause of cognitive decline in elderly individuals, with complex and multifactorial etiology. The traditional one drug-one target paradigm is not effective for AD and other complex disorders, highlighting the potential of the multitarget approach in treatment.

CURRENT NEUROPHARMACOLOGY (2021)

添加到收藏夹

Article Neurosciences

Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets

Md. Sahab Uddin et al.

Summary: Alzheimer's disease is a common form of dementia in elderly people, with approved medications including ChEIs and NMDAR antagonists. Single-target therapies have shown to be unsuccessful in treating the multifactorial symptoms or disease progression of Alzheimer's, highlighting the need for diverse pharmacological targets in treatment.

MOLECULAR NEUROBIOLOGY (2021)

添加到收藏夹

Review Chemistry, Medicinal

Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review

Daniela Malafaia et al.

Summary: Alzheimer's disease is a common form of dementia in the elderly with no cure currently available. Multi-target compounds show promise in addressing various factors related to AD. Accumulation of Aβ plaques and NFTs are key features of AD, attracting significant research attention for early diagnosis and treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice

Elisabet Viayna et al.

Summary: By combining the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaicin, compounds with nanomolar potencies towards AChE and BChE were created, demonstrating potential therapeutic effects for Alzheimer's disease.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?

Angela De Simone et al.

Summary: Alzheimer's disease is a result of systemic breakdown of different physiological networks, and targeting multiple biochemical targets or pathways may be more efficient in tackling the disease. Recent studies have shown efforts in developing MTDLs targeting GSK-3β enzyme, which has connections with AD pathogenesis.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis disfunction by the RhoA/ROCK pathway

Olmo Martin-Camara et al.

Summary: The morphology of synaptic spines is controlled by Rac1, Cdc42, and RhoA, with RhoA/ROCK playing a crucial role in stabilizing actin formation and preventing the generation of new protrusions. The RhoA/ROCK pathway influences plasticity processes and is implicated in various brain-related pathologies, highlighting its importance in drug discovery for neurodegenerative diseases.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

News Item Biotechnology & Applied Microbiology

2020 FDA drug approvals

Asher Mullard

Summary: In 2020, the FDA approved 53 novel drugs, the second highest count in over 20 years.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Review Chemistry, Medicinal

Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer's Disease

Marta Campora et al.

Summary: Alzheimer's disease is a progressive neurodegenerative disease characterized by memory loss, cognitive impairment, and functional decline. Research on new drugs for AD has focused on NQ and AQ derivatives, which have shown potential biological effects against AD and could be effective treatments for the disease.

PHARMACEUTICALS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity

Silvia Chaves et al.

Summary: Alzheimer's disease is the most common and severe neurodegenerative disorder worldwide, with currently available drugs providing only temporary symptomatic relief. Research indicates that the onset and progression of AD are influenced by multiple factors, highlighting the need for the development of multitarget-directed ligands to target various pathological pathways.

CURRENT MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy

Aurelien Beato et al.

Summary: Natural beta-carboline alkaloids show similarities with neurotransmitters, which can be exploited to design drugs for Alzheimer's disease therapy. Current research focuses on investigating different hypotheses related to AD, with the beta-carboline scaffold identified as a powerful tool for interacting with a wide range of AD-related targets to design multitarget-directed ligands.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Beyond Antioxidant Effects: Nature-Based Templates Unveil New Strategies for Neurodegenerative Diseases

Andrea Bacci et al.

Summary: The pathogenesis of neurodegenerative diseases is complex, making drug development challenging. Redox reactions play a crucial role in maintaining neuronal microenvironment homeostasis. A shift in drug discovery methods towards innovative polypharmacology approaches is gradually occurring in order to tackle the relentless progress of these diseases.

ANTIOXIDANTS (2021)

添加到收藏夹

News Item Medicine, General & Internal

Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Review Chemistry, Multidisciplinary

Current Strategies for Modulating Aβ Aggregation with Multifunctional Agents

Zhi Du et al.

Summary: This article discusses the progress in the research field of Alzheimer's disease (AD), focusing on various methods and mechanisms for regulating amyloid-beta (A beta) aggregation, as well as the development of multifunctional therapeutic drugs and nanoparticles for comprehensive treatment of AD.

ACCOUNTS OF CHEMICAL RESEARCH (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity

Wojciech K. Jankiewicz et al.

Summary: The study found that the dual sEH/COX-2 inhibitor PTUPB can alleviate hypertension and proteinuria induced by antiangiogenic therapy, and it has a protective effect on kidney tissue and function.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Promising tacrine/huperzine A-based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget

Shinghung Mak et al.

Summary: Neurodegenerative disorders like Alzheimer's and Parkinson's diseases are devastating in the elderly population, with current treatments only able to alleviate symptoms. Collaborative research has led to the development of dimeric acetylcholinesterase inhibitors that may have disease-modifying effects through multiple pathways.

JOURNAL OF NEUROCHEMISTRY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer's disease

Changjun Zhang et al.

Summary: Alzheimer's disease (AD) is a common neurodegenerative disorder among seniors worldwide. MAO inhibitors are gaining attention for their potential roles in AD treatment, especially with the development of novel MAO-B inhibitors as multitarget drugs. This review focuses on the recent progress in designing multifunctional ligands based on MAO-B inhibition for AD therapy.

BIOORGANIC CHEMISTRY (2021)

添加到收藏夹

Review Chemistry, Medicinal

Multitarget therapeutic approaches for Alzheimer's and Parkinson's disease: an opportunity or an illusion?

Maria Joao Matos

Summary: Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative diseases globally, with no cure currently available. There is an urgent need for multi-targeted therapeutic approaches to effectively manage these conditions.

FUTURE MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways

Stefania Demuro et al.

Summary: Protein kinases are crucial in CNS diseases, but the failure of clinical trials and drug development processes have posed challenges in treating neurological disorders. Recent drug design strategies have shown progress in developing disease-modifying agents for CNS diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Chemistry, Medicinal

Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist

Xiangqian Li et al.

Summary: The development of multitarget-directed ligands (MTDLs) is a widely focused research topic, but rational design remains a challenge. Strategies for designing MTDLs include merging lead compounds with similar functional groups, fusing key pharmacophores directly, and using the linked-pharmacophore strategy. The pharmacophores of second targets should not affect the binding mode of the original ones, and the inhibitory activities of the two targets need to be adjusted.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Clinical Neurology

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease

Niels D. Prins et al.

Summary: The 24-week treatment with 40 mg neflamapimod twice daily did not improve episodic memory in patients with mild AD, but it did lower CSF biomarkers of synaptic dysfunction. Further studies with longer duration and higher dose levels of neflamapimod are warranted to assess effects on AD progression.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease

Kamil Borkowski et al.

Summary: This study analyzed lipid mediators in plasma and cerebrospinal fluid of individuals with Alzheimer's disease and healthy controls, finding elevated cytochrome P450/soluble epoxide hydrolase pathway components and decreased fatty acid ethanolamides in Alzheimer's disease patients. The results suggest potential therapeutic benefits of targeting both metabolic pathways for Alzheimer's disease treatment.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Alzheimer's disease drug development pipeline: 2021

Jeffrey Cummings et al.

Summary: Overall, the study highlights the urgent need for new treatments for Alzheimer's disease, and shows that a diverse range of drugs targeting the biology of AD are being explored in clinical trials. Biomedical biomarkers are also being increasingly used in these trials to assess effectiveness.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Tacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments

Oscar M. Bautista-Aguilera et al.

Summary: The review highlights recent developments in identifying new tacrine analogues for Alzheimer's disease therapy, focusing on non-hepatotoxic tacrines and the design of multitarget tacrines. Tacrine, the first approved cholinesterase inhibitor for AD, did not stop disease progression and had significant hepatotoxic effects, leading to its withdrawal from clinical use. Efforts are now being made to develop safer tacrine derivatives and multitarget compounds to target other biological mechanisms involved in AD.

CHEMICAL RECORD (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recent Advances in the Rational Drug Design Based on Multi-target Ligands

Ting Yang et al.

CURRENT MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Sodium Oligomannate: First Approval

Yahiya Y. Syed

DRUGS (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands

Aida Iraji et al.

BIOORGANIC CHEMISTRY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

A Perspective on Multi-target Drugs for Alzheimer's Disease

Ondrej Benek et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain

James Michael Brimson et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations

Samuele Maramai et al.

BIOMED RESEARCH INTERNATIONAL (2020)

添加到收藏夹

Review Chemistry, Medicinal

Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities

Daniel A. Rodrigues et al.

MEDICINAL RESEARCH REVIEWS (2020)

添加到收藏夹

Article Clinical Neurology

Phosphorylated tau interactome in the human Alzheimer's disease brain

Eleanor Drummond et al.

BRAIN (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy

Agnieszka Zagorska et al.

MOLECULES (2020)

添加到收藏夹

Article Clinical Neurology

Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease

Christian Grinan-Ferre et al.

NEUROTHERAPEUTICS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization

Hamad Yadikar et al.

PLOS ONE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015-Present: Synthesis and Biological Activity

Todd J. Eckroat et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Neurosciences

14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease

Wenjun Chen et al.

JOURNAL OF NEUROSCIENCE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Memantine Derivatives as Multitarget Agents in Alzheimer's Disease

Giambattista Marotta et al.

MOLECULES (2020)

添加到收藏夹

Review Neurosciences

Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs

Mark J. Millan et al.

NEUROPHARMACOLOGY (2020)

添加到收藏夹

Article Cell Biology

Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains

Christian Haenig et al.

CELL REPORTS (2020)

添加到收藏夹

Review Chemistry, Medicinal

Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease

Marcia Martins et al.

PHARMACEUTICALS (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer

Amarjyoti Das Mahapatra et al.

MOLECULES (2020)

添加到收藏夹

Article Cell Biology

An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease

Anamitra Ghosh et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

Alzheimer's disease drug development pipeline: 2020

Jeffrey Cummings et al.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2020)

添加到收藏夹

Article Chemistry, Medicinal

Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds

Ewgenij Proschak et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity

Kerstin Hiesinger et al.

PROSTAGLANDINS & OTHER LIPID MEDIATORS (2019)

添加到收藏夹

Article Chemistry, Medicinal

Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms

Junting Zhou et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Review Chemistry, Medicinal

Multi-target design strategies for the improved treatment of Alzheimer's disease

Pengfei Zhang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development

Knut Biber et al.

FRONTIERS IN PHARMACOLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Cognitive symptoms of Alzheimer's disease: clinical management and prevention

Elizabeth Joe et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

History and progress of hypotheses and clinical trials for Alzheimer's disease

Pei-Pei Liu et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes

Md Abdul Hye Khan et al.

DIABETOLOGIA (2018)

添加到收藏夹

Review Neurosciences

Alzheimer's disease hypothesis and related therapies

Xiaoguang Du et al.

TRANSLATIONAL NEURODEGENERATION (2018)

添加到收藏夹

Review Cell Biology

Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation

Sonia Villapol

CELLULAR AND MOLECULAR NEUROBIOLOGY (2018)

添加到收藏夹

Review Neurosciences

Therapeutics of Neurotransmitters in Alzheimer's Disease

Ramesh Kandimalla et al.

JOURNAL OF ALZHEIMERS DISEASE (2017)

添加到收藏夹

Article Chemistry, Medicinal

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis

Jurema Schmidt et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1

Laura Schnoeder et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2016)

添加到收藏夹

Review Neurosciences

CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease

Ester Aso et al.

FRONTIERS IN NEUROSCIENCE (2016)

添加到收藏夹

Review Cell Biology

Tau protein kinases: Involvement in Alzheimer's disease

Ludovic Martin et al.

AGEING RESEARCH REVIEWS (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Human Disease and Drug Pharmacology, Complex as Real Life

E. Viayna et al.

CURRENT MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Article Geriatrics & Gerontology

Activation of the CB2 receptor system reverses amyloid-induced memory deficiency

Jiang Wu et al.

NEUROBIOLOGY OF AGING (2013)

添加到收藏夹

Article Chemistry, Medicinal

Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering

Daniel Moser et al.

ACS MEDICINAL CHEMISTRY LETTERS (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Interactome mapping suggests new mechanistic details underlying Alzheimer's disease

Montserrat Soler-Lopez et al.

GENOME RESEARCH (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

Travis T. Wager et al.

ACS CHEMICAL NEUROSCIENCE (2010)

添加到收藏夹

Review Chemistry, Medicinal

Multi-target-directed ligands to combat neurodegenerative diseases

Andrea Cavalli et al.

JOURNAL OF MEDICINAL CHEMISTRY (2008)

添加到收藏夹

Review Biochemistry & Molecular Biology

Network pharmacology: the next paradigm in drug discovery

Andrew L. Hopkins

NATURE CHEMICAL BIOLOGY (2008)

添加到收藏夹

Article Chemistry, Medicinal

The physicochemical challenges of designing multiple ligands

Richard Morphy et al.

JOURNAL OF MEDICINAL CHEMISTRY (2006)

添加到收藏夹

Review Chemistry, Medicinal

Designed multiple ligands. An emerging drug discovery paradigm

R Morphy et al.

JOURNAL OF MEDICINAL CHEMISTRY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.